ReviewCancer research2015
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.
Review in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- Obesity-Related Coagulation Activation in Adolescents and Children: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Unravelling Ovarian Cancer: an analysis of the Influence of LRP1 and PAI1 Genetic Variations.Biochemical genetics · 2026Article
- Identification of novel paracrine therapeutic targets in peritoneal metastases through integrative proteotranscriptomic analysis of ascites.Molecular cancer · 2026Article
- Angiogenic behavior of human umbilical vein endothelial cells in hydrogel containing lyophilized powder of decellularized adipose tissue from high-fat diet-fed or exercise-trained rats.Metabolism open · 2026Article
- Plasminogen Activation System and Fibroblasts: Impact on Tissue Remodeling, Disease, and Organ Homeostasis.Inflammation · 2026Review
- Review
- A contemporary review of plasminogen activator inhibitor 1 in cardiovascular disease and broader disease state implications.Blood vessels, thrombosis & hemostasis · 2026Review
- Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.Journal of proteome research · 2026Article
- Targeted Interference with USF2 Binding to the SERPINE1 Proximal Promoter E-Box in Dual Mutant p53Biomedicines · 2026Review
- PAI-1 is a common driver of aging and diverse diseases.Biomedical journal · 2026Review
- Microenvironment-defined priority pathways shape ICD-driven abscopal responses.Frontiers in immunology · 2026Review
- Plasminogen activator inhibitor-1 as an oncologic target: biology, therapeutic inhibitors, and clinical translation.Frontiers in oncology · 2026Review
- Rather a versatile multi-tool than a sword: an integral role of the plasminogen system in health and disease.Frontiers in immunology · 2026Review
- PAI-1: A Key Signal at the Crossroads of Stem Cell Differentiation and Senescence.International journal of molecular sciences · 2025Review
- [SERPINE1 overexpression promotes proliferation and paclitaxel resistance of triple-negative breast cancer cells by inducing M2 macrophage polarization].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- LCRMP-1 induces tumor angiogenesis by transcriptionally upregulating SERPINE1 in lung adenocarcinoma.Communications biology · 2025Article
- PAI-1 in Skin Malignancies: a Central Regulator of Tumor Progression and Therapeutic Resistance.Current treatment options in oncology · 2025Review
- HIF-2α Interaction with Ataxin-10 Enhances HIF-2α Binding to Its Target Gene Promoters.International journal of molecular sciences · 2025Article
- Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.